Neuland Laboratories

Neuland Laboratories Liabilities

The The Liabilities of Neuland Laboratories (NEULANDLAB.NS) as of Nov 4, 2026 is 10.56 B INR. In the previous year, The Liabilities was 6.55 B INR — a change of 61.15% (higher).

Liabilities

10.56 BINR

YoY

61.15%

Last updated:

In 2026, Neuland Laboratories's total liabilities amounted to 10.56 B INR, a 61.15% difference from the 6.55 B INR total liabilities in the previous year.

The Neuland Laboratories Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
4.31 B INR
Jan 1, 2020
5.21 B INR
Jan 1, 2021
5.38 B INR
Jan 1, 2022
5.43 B INR
Jan 1, 2023
5.86 B INR
Jan 1, 2024
5.50 B INR
Jan 1, 2025
6.55 B INR
Jan 1, 2026
10.56 B INR
The Neuland Laboratories Liabilities history
YEARLiabilitiesYoY
10.56 BINR+61.15%
6.55 BINR+19.14%
5.50 BINR-6.11%
5.86 BINR+7.86%
5.43 BINR+0.87%
5.38 BINR+3.32%
5.21 BINR+20.87%
4.31 BINR-16.03%
5.13 BINR+51.00%
3.40 BINR+0.76%
3.37 BINR-3.57%
3.50 BINR-2.60%
3.59 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Neuland Laboratories's Liabilities

Neuland Laboratories's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Neuland Laboratories's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Neuland Laboratories's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Neuland Laboratories's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Neuland Laboratories’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Neuland Laboratories stock

The Liabilities of Neuland Laboratories is 10.56 B INR in 2026.

The Liabilities of Neuland Laboratories changed from 6.55 B INR to 10.56 B INR, representing a 61.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Neuland Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Neuland Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Neuland Laboratories